19 June 2020: any MRCA Treatment Pathway 1 and Treatment Pathway 2 information below has been retained for historical purposes only. A Single Treatment Pathway has been in effect since 12 December 2019. See section 8.1 Overview for current information.
Determination of claims for liability and compensation (including treatment) are made in accordance with section 333 of the MRCA. In relation to treatment this means any decision pursuant to paragraph 271(1)(c), 271(2)(c), 272(b) and 273(c) that treatment was reasonable in the circumstances. The delegation for section 333 is at the APS 5 level and above.
A — PS 3 level delegates and above are able to determine the amount of compensation payable for Pathway 1 treatment pursuant to section 276(1).
Further information on delegations is contained at paragraph 1.3 in Chapter 1 of this manual.